Safety and Adherence of a Non-medicated Intravaginal Ring (IVR) (MTN-005)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01268332|
Recruitment Status : Completed
First Posted : December 30, 2010
Last Update Posted : August 15, 2017
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: Non-medicated Intravaginal Ring||Phase 2|
Women comprise a growing proportion of new HIV infections worldwide. Intravaginal rings (IVRs) used to deliver microbicides have the potential to significantly reduce the heterosexual transmission of HIV if found to be safe, acceptable, and effective against HIV infection. This study will investigate the safety and acceptability of a non-medicated silicone elastomer IVR in sexually active HIV uninfected women.
The expected duration of this study for each participant is 16 weeks. Study participants will be randomly assigned to one of two arms. Participants in Group A will insert an IVR into their vagina at study entry. The IVR will remain in place for 12 weeks until removed by a physician. Follow up will continue for an additional 4 weeks after IVR removal. Participants in Group B will not receive an IVR, but will follow the same study schedule as those in Group A.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||195 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Expanded Safety and Adherence Study of a Non-medicated Intravaginal Ring|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||March 7, 2013|
Experimental: Intravaginal Ring
Insertion of intravaginal ring at enrollment. The intravaginal ring should stay in place for 12 consecutive weeks and will be removed by a physician at the Week 12 study visit.
Drug: Non-medicated Intravaginal Ring
Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
Other Name: Placebo Intravaginal Ring
No Intervention: No Intravaginal Ring
Intravaginal ring will not be inserted into participants.
- Adherence to intravaginal ring [ Time Frame: Throughout study ]
- Grade 2 or higher adverse event [ Time Frame: Throughout study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01268332
|United States, Alabama|
|University of Alabama at Birmingham|
|Birmingham, Alabama, United States|
|United States, New York|
|Bronx-Lebanon Hospital Center|
|The Bronx, New York, United States|
|National AIDS Research Institute|
|Study Chair:||Craig Hoesley, MD||University of Alabama at Birmingham|